Interferon-α delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases

Hepatology

Volumn 33, Issue 2, 2001, Pages 346-356

  Murphy, Derek ^a   Detjen, Katharina M ^a   Welzel, Martina ^a   Wiedenmann, Bertram ^a   Rosewicz, Stefan ^a  

^a Medizinische Klinik   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE; HISTONE H1; JANUS KINASE; PROTAMINE KINASE; PROTEIN KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN;

APOPTOSIS; ARTICLE; CELL COUNT; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL STRAIN HEPG2; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; FLOW CYTOMETRY; GENE CONSTRUCT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; WESTERN BLOTTING;

EID: 0035146416     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2001.21749     Document Type: Article

References (74)

1. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan
2. Hepatitis C virus and hepatocellular carcinoma
3. Hepatitis C and alcohol
4. Aflatoxin and liver cancer
5. Genetic aspects of hepatocellular carcinogenesis
6. Molecular aspects of hepatocellular carcinoma
7. High frequency of p161NK4A gene alterations in hepatocellular carcinoma
8. TP53 and hepatocellular carcinoma
9. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma
10. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: Improved survival of surgically resected patients, 1985-1996
11. Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957
12. Cytokine therapeutics: Lessons from interferon alpha
13. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
14. Chronic hepatitis B virus infection: Treatment strategies for the next millennium
15. Antiviral therapy of HBV- and HCV-induced liver cirrhosis
16. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial
17. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study
18. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
19. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa
20. Delayed clearance of serum HBsAg in compensated cirrhosis B: Relation to interferon alpha therapy and disease prognosis
21. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C
22. Benefit of interferon-alpha2b in a patient with unresectable hepatoma and chronic infection with hepatitis C virus
23. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma
24. The interferon receptors
25. The Janus protein tyrosine kinase family and its role in cytokine signaling
26. How does interferon exert its cell growth inhibitory effect?
27. Role of G0-G1 arrest in the inhibition of tumor cell growth by interferon
28. Interferon-beta induces S phase accumulation selectively in human transformed cells
29. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines
30. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21
31. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines
32. Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor
33. The role of STATs in transcriptional control and their impact on cellular function
34. Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma
35. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway
36. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
37. Inactivation of p161NK4 in hepatocellular carcinoma
38. Mutations and altered expression of p161NK4 in human cancer
39. Mutational analysis of p73 and p53 in human cancer cell lines
40. Adenovirally transferred p161NK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death
41. Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways
42. Establishment of two distinct human hepatocellular carcinoma cell lines from a single nodule showing clonal dedifferentiation of cancer cells
43. Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest
44. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth-sensitive hematopoietic cells
45. Interferon-alpha inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells
46. Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: Role in growth regulation
47. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins
48. Differential myeloma cell responsiveness to interferon-alpha correlates with differential induction of p19(INK4d) and cyclin D2 expression
49. Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages
50. A role for the cyclin-dependent kinase inhibitor p21 in the G1 cell cycle arrest mediated by the type I interferons
51. Interferon-induces expression of cyclin-dependent kinase-inhibitors p21WAF1 and p27Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)
52. Activation of the human p27(Kip1) promoter by IFNalpha 2b
53. The p16INK4a/CDKN2A tumor suppressor and its relatives
54. CDK inhibitors: Positive and negative regulators of G1-phase progression
55. Ginsenoside-Rs4, a new type of ginseng saponin concurrently induces apoptosis and selectively elevates protein levels of p53 and p21WAF1 in human hepatoma SK-HEP-1 cells
56. Ginsenoside-Rs3, a new diol-type ginseng saponin, selectively elevates protein levels of p53 and p21WAF1 leading to induction of apoptosis in SK-HEP-1 cells
57. Interferon potentiates antiproliferative activity of CPT-11 against human colon cancer xenografts
58. Inhibition of cell division by interferon: Changes in cell cycle characteristics and in morphology of Ehrlich ascites tumour cells in culture
59. Block of glioma cell line in S by interferon
60. Effect of interferon-beta on the cell cycle of human glioma cell line U- 251 MG: Flow cytometric two-dimensional (BrdU/DNA) analysis
61. Relationship between the enhanced expression of histocompatibility antigens on interferon-treated L 1210 cells and their position in the cell cycle
62. Cyclin A is required in S phase in normal epithelial cells
63. Inhibition of DNA synthesis by downregulation of cyclin A but not Skp 2 overexpression in human hepatocellular carcinoma cells
64. Overexpression of cyclin A but not Skp 2 correlates with the tumor relapse of human hepatocellular carcinoma
65. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma
66. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
67. Cancer cell cycles
68. Effect of cyclins and Cdks on the cyclin B1 promoter activation
69. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes
70. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells
71. cdc25 is a specific tyrosine phosphatase that directly activates p34cdc2
72. Dephosphorylation and activation of a p34cdc2/cyclin B complex in vitro by human CDC25 protein
73. Hyperphosphorylation of the N-terminal domain of Cdc25 regulates activity toward cyclin B1/Cdc2 but not cyclin A/Cdk2
74. p55CDC25 is a nuclear protein required for the initiation of mitosis in human cells